Oncology Central

Safety and efficacy of preoperative sorafenib therapy in facilitating cytoreductive surgery in renal cell carcinoma


With 65,000 new cases in the USA in 2013, the incidence of kidney cancer has doubled in last decade and accounted for 13,600 deaths in 2013 [1,2]. Renal cell carcinoma (RCC), which consists of 80% of kidney cancers in adults [3], presents with advanced or metastatic stage in approximately a third of patients. A third of early-stage RCC will subsequently recur or progress to metastatic disease after initial nephrectomy [4].

To view restricted content, please:

Leave A Comment